Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Trevi Therapeutics Inc (TRVI)

Trevi Therapeutics Inc (TRVI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,366,144
  • Shares Outstanding, K 128,397
  • Annual Sales, $ 0 K
  • Annual Income, $ -42,760 K
  • EBIT $ -49 M
  • EBITDA $ -49 M
  • 60-Month Beta 0.94
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 7.53

Options Overview Details

View History
  • Implied Volatility 142.86% (+22.14%)
  • Historical Volatility 60.79%
  • IV Percentile 79%
  • IV Rank 44.09%
  • IV High 263.53% on 02/18/26
  • IV Low 47.69% on 08/22/25
  • Expected Move (DTE 23) 1.55 (13.52%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 840
  • Volume Avg (30-Day) 505
  • Put/Call OI Ratio 0.42
  • Today's Open Interest 16,655
  • Open Int (30-Day) 17,683
  • Expected Range 9.89 to 12.99

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.07
  • Number of Estimates 7
  • High Estimate -0.06
  • Low Estimate -0.09
  • Prior Year -0.09
  • Growth Rate Est. (year over year) +22.22%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.25 +11.61%
on 03/24/26
13.55 -15.57%
on 03/06/26
+0.08 (+0.70%)
since 02/25/26
3-Month
9.82 +16.50%
on 02/19/26
13.55 -15.57%
on 03/06/26
-1.53 (-11.80%)
since 12/24/25
52-Week
4.85 +135.88%
on 04/10/25
14.39 -20.50%
on 12/10/25
+4.83 (+73.07%)
since 03/25/25

Most Recent Stories

More News
Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates 

Following the End-of-Phase 2 meeting with the FDA, the Company gained alignment on its Phase 3 program for the treatment of patients with idiopathic pulmonary fibrosis-related chronic cough On...

TRVI : 11.44 (+7.52%)
Trevi Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results and Provide Business Updates on March 17, 2026

NEW HAVEN, Conn., March 10, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...

TRVI : 11.44 (+7.52%)
Trevi Therapeutics Announces Completion of End-of-Phase 2 Meeting with the FDA, Gaining Alignment for Its Development Program for Idiopathic Pulmonary Fibrosis-Related Chronic Cough

T he Company will conduct two Phase 3 clinical trials of nalbuphine ER for the treatment of patients with IPF-related chronic cough First pivotal trial is on track to initiate in the second quarter...

TRVI : 11.44 (+7.52%)
Trevi Therapeutics to Participate in Upcoming March Conferences

NEW HAVEN, Conn., March 02, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...

TRVI : 11.44 (+7.52%)
Trevi Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

NEW HAVEN, Conn., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...

TRVI : 11.44 (+7.52%)
Trevi Therapeutics Announces Publication of Data from the Phase 2b IPF Chronic Cough Trial of nalbuphine ER in the Journal of the American Medical Association (JAMA)

Statistically-s ignificant reduction in the relative change from baseline in 24-hour objective cough frequency observed across all dose groups of nalbuphine ER at Week 6 with statistically-significant...

TRVI : 11.44 (+7.52%)
Trevi Therapeutics Provides Strategic Updates Ahead of Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference

FDA End-of-Phase 2 meeting scheduled to take place in the first quarter of 2026 for the chronic cough program in patients with idiopathic pulmonary fibrosis

TRVI : 11.44 (+7.52%)
Trevi Therapeutics Announces Appointment of David Hastings as Chief Financial Officer

Experienced biotech CFO to lead financial strategy and contribute to the Company's next stage of growth

TRVI : 11.44 (+7.52%)
Trevi Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates

Company preparing to initiate comprehensive Phase 3 program for chronic cough in patients with idiopathic pulmonary fibrosis in first half of 2026

TRVI : 11.44 (+7.52%)
Trevi Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 13, 2025

Conference call and webcast to be held at 4:30 p.m. ET

TRVI : 11.44 (+7.52%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Buy with a Weakest short term outlook on maintaining the current direction.

Relative Strength just crossed above 50%. The market is indicating support for a bullish trend.

See More Share

Business Summary

Trevi Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. The company is currently developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in...

See More

Key Turning Points

3rd Resistance Point 12.93
2nd Resistance Point 12.34
1st Resistance Point 11.89
Last Price 11.44
1st Support Level 10.84
2nd Support Level 10.25
3rd Support Level 9.80

See More

52-Week High 14.39
Last Price 11.44
Fibonacci 61.8% 10.75
Fibonacci 50% 9.62
Fibonacci 38.2% 8.49
52-Week Low 4.85

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.